Foundation Medicine, Inc. announced a global collaboration with Karyopharm Therapeutics Inc. to develop FoundationOneCDx as a companion diagnostic for selinexor, which is being evaluated as a front-line maintenance therapy following systemic therapy in patients with advanced or recurrent TP53 wild-type endometrial cancer. Endometrial cancer is the most common cancer of the female reproductive organs in the U.S. Roughly 50% of patients with advanced or recurrent disease have p53 wild-type tumors. Karyopharm's phase 3 study (EC-042; NCT03555422) is a multicenter, blinded, placebo-controlled, randomized study evaluating the efficacy and safety of selinexor as a maintenance therapy following systemic therapy in patients with advanced or recurrent TP53 wild-type endometrial cancer.

The study is utilizing Foundation Medicine's tissue-based next generation sequencing test to identify and enroll patients whose tumors are TP53 wild-type. Foundation Medicine's portfolio of FDA-approved comprehensive genomic profiling tests offers physicians both blood- and tissue-based testing options for detecting genomic alterations that help guide personalized treatment decisions. If approved, FoundationOneCDx would be the first companion diagnostic to identify patients with TP53 wild-type endometrial cancer who may be eligible for selinexor.